Kamran Hosseini, MD, PhD
Chief Executive Officer
Kamran Hosseini, MD, PhD has over 20 years of experience in the field of ophthalmology drug & device development. Most recently, as Site Lead & Chief Medical Officer at Insite Vision Inc., he oversaw clinical, pre-clinical, CMC, manufacturing, regulatory affairs, and drug development programs. He led the approval of AzaSite™ in Canada & BromSite™ in USA. Prior to InSite, he was the resident expert and a member of the Ophthalmology Task Force of J&J and director of the ocular drug delivery program at Alza Corporation (a J&J company). He has over 20 patents in drug delivery (filed & issued) and has (co-)authored over 60 scientific & clinical publications.
He obtained a M.D. degree from the University of Groningen in The Netherlands. In collaboration with the Department of Ophthalmology of the Academic Hospital Maastricht, he completed a Ph.D. program while serving as Assistant Professor of Ophthalmology at the University of Texas Medical Branch in Galveston, TX. He also completed a post-doctoral fellowship in retinal degenerative diseases at the University of California in San Francisco.
Preeya K. Gupta, MD
Chief Medical Advisor
Preeya K. Gupta, MD, is a tenured Associate Professor of Ophthalmology at Duke University Eye Center in Durham, North Carolina.
Dr. Gupta earned her medical degree at Northwestern University’s Feinberg School of Medicine in Chicago, and graduated with Alpha Omega Alpha honors. She fulfilled her residency in ophthalmology at Duke University Eye Center in Durham, North Carolina, where she earned the K. Alexander Dastgheib Surgical Excellence Award, and then completed a fellowship in Cornea and Refractive Surgery at Minnesota Eye Consultants in Minneapolis.
Dr. Gupta is an active member of the American Society of Cataract and Refractive Surgery (ASCRS) clinical committees and is also the past President of the Vanguard Ophthalmology Society. She has been named to the Ophthalmology Power list multiple times and is an active educator, having given numerous lectures both nationally and internationally. Her clinical interests include ocular surface disease, cataract and refractive surgery.
Chief Financial Officer
Ken Owyang is a seasoned private and public company CFO who brings more than 25 years of experience with high-growth companies across a variety of dynamic industries. As an operationally-focused executive, he has a passion for scaling businesses from start-up to public company, including two IPO and over $100 million raised in private debt and equity financings. Ken was formerly the CFO of Trion Worlds, Inc., Support.com (NASDAQ: SPRT), Marimba, Inc. (NASDAQ: MRBA). Ken started his career with PWC and earned his bachelor’s degree in Business Administration from San Francisco State University.
Perry J. Sternberg
Perry Sternberg, who currently serves as President and Chief Executive Officer for Corium, Inc., brings more than 25 years of experience in the biotechnology and pharmaceutical industries, with commercial experience across a wide range of therapeutic areas, including ophthalmics, in diverse markets.
Sternberg spent time working with therapies for both the anterior and posterior segments of the eye while at Novartis Ophthalmics, Bausch + Lomb, and, most recently, Shire. At Shire, one of his areas of responsibility was establishing the Global Ophthalmics Business Unit and bringing Xiidra® to the U.S. Market.
During the course of his career, he has had direct responsibility for launch and commercialization of more than twenty products. Hallmarks of Mr. Sternberg’s business style and success are his unrelenting focus on exceeding the needs of customers and bringing out the optimal performance in his teams.
He holds a bachelor’s degree in Animal Bioscience from Pennsylvania State University.
Richard Lindstrom, MD
Dr. Lindstrom is a founder, director and has been an attending surgeon at Minnesota Eye Consultants P.A., a provider of eye care services, since 1989. Dr. Lindstrom has served as a researcher, teacher, inventor, writer, lecturer and highly acclaimed physician and surgeon in the ophthalmology field. He has also served as a member of the board of directors of TearLab Corporation since 2010 and Ocular Therapeutix, Inc. since 2012. Dr. Lindstrom has also served as associate director of the Minnesota Lions Eye Bank since 1987 and he is a medical advisor for several medical device and pharmaceutical manufacturers and serves on the boards of several other privately-held life sciences companies. Dr. Lindstrom previously served as president of the International Society of Refractive Surgery from 1993 to 1994, the International Intraocular Implant Society from 2002 to 2004, the International Refractive Surgery Club from 2002 to 2004, and the American Society of Cataract and Refractive Surgery from 2007 to 2008. Dr. Lindstrom currently serves on the ASCRS Executive Committee and is a board member of the ASCRS Foundation. From 1980 to 1989, he served as a professor of ophthalmology at the University of Minnesota, where he is currently an adjunct professor emeritus. Dr. Lindstrom is also a board member of the University of Minnesota Foundation, chairing the Ophthalmology and Visual Neurosciences Division. Dr. Lindstrom holds a B.A. degree in Pre-Medical Studies, a B.S. degree in Medicine and an M.D. degree from the University of Minnesota. Dr. Lindstrom brings to the Board over 30 years of ophthalmology industry experience, as well extensive experience serving as a director of other companies.
Adrienne Graves, Ph.D.
Dr. Adrienne Graves is a visual scientist by training and a global industry leader in ophthalmology. As the former CEO of Santen Inc., the US subsidiary of a 130 year old Japanese pharmaceutical company, she successfully established a strong global presence, brought multiple ophthalmic products through development to approval and commercialization, and led global teams through successful acquisitions and partnerships. At Santen, Dr. Graves served as Sr. VP of Worldwide Clinical Development (US, Europe, and Japan) for 7 years and CEO for 8 years. Prior to Santen, she spent 9 years at Alcon, joining as Sr. Scientist to establish Alcon’s first Retinal Electrophysiology Laboratory. She progressed through roles of increasing responsibility in R&D, including directing clinical development in multiple therapeutic areas and serving as Director of International Ophthalmology.
Dr. Graves currently serves as an Independent Director on the boards of Iveric Bio, Qlaris Bio, Nicox S.A., Surface Ophthalmics, Oxurion, TherOptix, and Greenbrook TMS. She previously held board positions at Encore Vision (2011 – 2017; acquired by Novartis), Envisia Therapeutics (2014 – 2017; assets acquired by Aerie Pharmaceuticals), TearLab Corporation (2005 – 2018), Aerpio Therapeutics (2012 – 2017), and Akorn (2012 – 2020). Dr. Graves also serves as Director on the following Foundation Boards: American Society of Cataract and Refractive Surgery (ASCRS) Foundation, Glaucoma Research Foundation, American Academy of Ophthalmology Foundation (Emeritus), Retina Global, Himalayan Cataract Project, Foundation Fighting Blindness (FFB), and the RD (Retinal Degeneration) Fund. She co-founded OWL (Ophthalmic World Leaders, formerly Ophthalmic Women Leaders) and Glaucoma 360, and is a Visionary Innovation Mentor at the Stanford University Ophthalmic Innovation Program. Her recent honors include the Visionary Award from Foundation Fighting Blindness, the Catalyst Award from Glaucoma Research Foundation, and the Visionary Award from OWL. Dr. Graves received an AB with Honors in Psychology from Brown University, a Ph.D. in Psychobiology/ Neuroscience from the University of Michigan, and she completed a Postdoctoral Fellowship in Visual Neuroscience at the University of Paris.
Shelley Thunen joined as a member of our board of directors and chair of the audit committee in August 2020. Since January 2016, Ms. Thunen has served as the Chief Financial Officer of RxSight, Inc., a privately held medical device company, that developed and markets the world’s only adjustable intraocular lens for cataract surgery.
Prior to joining RxSight, Ms. Thunen has held financial and operations leadership roles in several medical device and vision care companies, including Endologix, Inc., LenSx, Inc., and IntraLase Corp. In these roles, she advanced companies responsible for innovations in eye care such as the first femtosecond laser for cataract surgery (LenSx) and the first femtosecond laser to create the corneal flap as the first step to LASIK surgery (IntraLase). Prior Board of Directors and audit chair experience includes: Restoration Robotics, Inc., a publicly held company, acquired in 2019; LenSx Lasers, Inc., acquired in 2010; and eyeonics, Inc. acquired in 2008. Ms. Thunen received a B.A. in economics and an M.B.A. from the University of California, Irvine.
Mark Baum, JD
Mark L. Baum is the founder of and serves as the CEO of Harrow Health, Inc. (NASDAQ: HROW). For the 2014-2017 periods, Harrow (formerly Imprimis Pharmaceuticals) was named by Deloitte’s Technology Fast 500™ as one of the fastest growing companies in North America. Mr. Baum is also a founder of Eton Pharmaceuticals (NASDAQ: ETON), as well as a founder and board member of Surface Ophthalmics, Melt Pharmaceuticals, and Visionology.com. From 2014-2017, Mr. Baum was a senior advisor to Curology.com, a leading tele-dermatology platform. Prior to Harrow, as the founder of TBLF, LLC, a private investment fund manager, Mr. Baum made more than 200 investments into more than 40 private and public companies. In 1999, Mr. Baum founded YesRx, an HIV-focused pharmacy business. Mr. Baum’s advocacy for drug pricing and patient and physician prescription medication accessibility issues has been featured in Op-Ed contributions for the Wall Street Journal and through appearances on numerous national media outlets. Mr. Baum was named by Ernst & Young LLP as the 2017 Entrepreneur of the Year™ in the life sciences category for the San Diego region. Mr. Baum is a graduate, cum laude, of The University of Texas at Arlington and a 1997 graduate of California Western School of Law.
J. Andy Corley
J. Andy Corley is a veteran executive with focus on ophthalmology startups. He has experience building startups and taking them through product commercialization, financing, and acquisitions. He is a co-founder of the Flying L Partnership. He is currently Chairman of the Board of RxSight, Equinox, and eyeBrain Medical.